A study compared the effectiveness of TNF inhibitors, JAK inhibitors, and IL-17 inhibitors in improving the SPARCC score of the sacroiliac joint in patients with axial spondyloarthritis. The analysis included 18 randomized controlled trials, which showed that all three types of inhibitors were equally effective in reducing the SIJ SPARCC score at 3 months. TNF inhibitors were more effective at reducing scores after 48 to 52 weeks, but the difference was not statistically significant. The study concluded that TNF inhibitors, IL-17 inhibitors, and JAK inhibitors are equally effective in reducing SIJ SPARCC score in active axSpa patients at 3 months, with the potential for more significant reductions at 1 year.
Source link
Treatment With DMARDs May Improve Sacroiliac Joint MRI Scores in Axial Spondyloarthritis
